- Home
- ONFO vs PSTV Comparison
ONFO vs PSTV Comparison
Compare ONFO & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONFO
- PSTV
- Stock Information
- Founded
- ONFO 2018
- PSTV 1996
- Country
- ONFO United States
- PSTV United States
- Employees
- ONFO N/A
- PSTV N/A
- Industry
- ONFO Computer Software: Programming Data Processing
- PSTV Medical/Dental Instruments
- Sector
- ONFO Technology
- PSTV Health Care
- Exchange
- ONFO Nasdaq
- PSTV Nasdaq
- Market Cap
- ONFO 5.8M
- PSTV 5.1M
- IPO Year
- ONFO 2022
- PSTV N/A
- Fundamental
- Price
- ONFO $0.96
- PSTV $0.33
- Analyst Decision
- ONFO
- PSTV Strong Buy
- Analyst Count
- ONFO 0
- PSTV 3
- Target Price
- ONFO N/A
- PSTV $13.00
- AVG Volume (30 Days)
- ONFO 9.2K
- PSTV 12.9M
- Earning Date
- ONFO 05-16-2025
- PSTV 05-30-2025
- Dividend Yield
- ONFO N/A
- PSTV N/A
- EPS Growth
- ONFO N/A
- PSTV N/A
- EPS
- ONFO N/A
- PSTV N/A
- Revenue
- ONFO $9,087,118.00
- PSTV $5,206,000.00
- Revenue This Year
- ONFO N/A
- PSTV $13.26
- Revenue Next Year
- ONFO N/A
- PSTV $8.84
- P/E Ratio
- ONFO N/A
- PSTV N/A
- Revenue Growth
- ONFO 65.97
- PSTV N/A
- 52 Week Low
- ONFO $0.61
- PSTV $0.24
- 52 Week High
- ONFO $1.88
- PSTV $2.58
- Technical
- Relative Strength Index (RSI)
- ONFO 43.22
- PSTV 38.75
- Support Level
- ONFO $0.98
- PSTV $0.28
- Resistance Level
- ONFO $1.02
- PSTV $0.66
- Average True Range (ATR)
- ONFO 0.04
- PSTV 0.07
- MACD
- ONFO 0.00
- PSTV 0.01
- Stochastic Oscillator
- ONFO 42.86
- PSTV 16.38
About ONFO Onfolio Holdings Inc.
Onfolio Holdings Inc actively manages small online businesses that operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by existing teams or have management teams largely in place.
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).